Alvine Pharmaceuticals, Inc. ALV003 Receives Fast Track Designation From the FDA for the Potential Treatment of Celiac Disease

Published: Sep 05, 2012

SAN CARLOS, Calif.--(BUSINESS WIRE)--Alvine Pharmaceuticals, Inc., a leader in celiac disease therapeutics development, announced today that its lead candidate, ALV003, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of patients with celiac disease. Alvine is currently conducting phase 2 clinical trials with ALV003.

Back to news